Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Samuraciclib - Carrick Therapeutics

Next Previous
X
Search
Drug Profile

Samuraciclib - Carrick Therapeutics

Alternative Names: CT-7001; ICEC-0942

Latest Information Update: 14 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Imperial College of Science, Technology and Medicine
  • Developer Carrick Therapeutics; Menarini; Pfizer
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Benzylamines; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II HER2 negative breast cancer
  • Phase I/II Solid tumours
  • No development reported Acute myeloid leukaemia; Breast cancer; Small cell lung cancer

Most Recent Events

  • 14 Jul 2024 3862712- Missing location added, Abstract contains trial design hence not covered
  • 10 Jan 2024 Pfizer initiated the phase Ib/II TACTIVE-U trial for HER-2 negative breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06125522)
  • 27 Nov 2023 Phase-II clinical trials in HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in Turkey, Spain (PO) (NCT05963984) (EudraCT2023-503903-27-00)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top